Dana Blankenhorn

Dana Blankenhorn

Expertise: Technology, Biotech, Renewable energy

Education: M.S,J. Northwestern (Medill School) 1978; B.A. Rice University, History and Political Science 1977

Awards & Accomplishments: Tech reporter since 1982, Freelance since 1983, on Internet since 1985. Created first online coverage of Internet with a magazine, Interactive Age, 1994 Co-wrote BBS Systems for Business in 1991, Wrote Guide to Field Computing in 1992 Wrote technology history now called "Living with Moore's Law" in 2001, 2010, 2021 Author of over a dozen books, both fiction and non-fiction

About Dana:
Dana Blankenhorn has been a financial journalist since 1978, a technology journalist since 1982, and an Internet journalist since 1985. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

He has written a half-dozen technology books, several novels available at the Amazon Kindle store, and covered beats ranging from education to e-commerce, and from open source to renewable energy. He lives in Atlanta.

Recent Articles

Why AT&T and Verizon Are Starting to Struggle

AT&T and Verizon are finding it hard to pay back their technology debt and the real debt they took on trying to get around it.

Piling Into Disney Stock Before Anything Happens

New Disney investors are betting it can make a success in streaming, but the numbers are daunting for DIS stock.

Why Investors Should Buy the Dip in MRK Stock

The fall in MRK, and other drug stocks, was based on fear of a drug price backlash that has not yet materialized.

Why Dead Oil Stocks Are Rising From the Grave

Better times have returned to the oilpatch with $65 per barrel oil, but these good times have a sell-by date for most oil stocks.

Investors Just Don’t Believe in Ford Stock Anymore

Ford stock yields 6.8%, but no one is buying because they question whether CEO Jim Hackett can ever beat General Motors in the big sales game

Amazon Is a Buy on Dips, Whatever Whole Foods Does

Amazon and Whole Foods have different cultures and different aims. AMZN stock can fix the problem, but it will take time.

This Is Why You Shouldn’t Count Regeneron Stock Out

When drug companies fall out of favor, as now, I look first to companies with a method for drug discovery like Regeneron stock.

Lyft and Zoom Offer Lessons for IPO Investors

Lyft investors are paying less for equity than previous private investors, while Zoom buyers get a profitable, fast-growing company.

Tesla’s Real Problem? It’s a Car Stock Priced Like a Tech Stock

Tesla stock has enormous short interest, and it's expected to lose money for the first quarter, but it's not going out of business, in fact it's growing.

Nokia Stock Is Still Waiting for the 5G Gold Rush

Analysts hope Nokia can earn 42 cents per share next year, which would make Nokia stock a bargain at $5.70. But over half no longer recommend the stock.